20.500.12556/DiRROS-12417
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : updated analysis of the observational GioTag study
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors.
non-small cell lung carcinoma - therapy
drug therapy
afatinib
osimertinib
GioTag study
nedrobnocelični karcinom pljuč - terapija
terapija z zdravili
afatinib
osimertinib
raziskava GioTag
true
false
true
Future Medicine Ltd
Angleški jezik
Ni določen
© 2019 Maximilian J Hochmair
Neznano
2020-09-11 14:42:57
2020-09-11 14:42:57
2022-08-18 03:37:19
0000-00-00 00:00:00
2019
0
Velika Britanija
0
Nasl. z nasl. zaslona;
Soavtorica iz Slovenije: Tanja Cufer;
Opis vira z dne 10. 1. 2020;
str. 2905-2914
iss. 25
Vol. 15
Sep. 2019
0000-00-00
Zaloznikova
Objavljeno
NiDoloceno
0000-00-00
0000-00-00
0000-00-00
616.2
1744-8301
10.2217/fon-2019-0346
2048610929
521824025
RAZ_Hochmair_Maximilian_J_i2019.pdf
RAZ_Hochmair_Maximilian_J_i2019.pdf
1
AE826F62EC54CB83F71667FE803EEB71
f91534d1ad8755591965ae1d8e03359d21baedecbc49ede8d697d1f7f0fe4a48
8dbf29be-17b6-11ed-b6b8-001a4af901a5
https://dirros.openscience.si/Dokument.php?lang=slv&id=17310
RAZ_Hochmair_Maximilian_J_i2019.pdf
RAZ_Hochmair_Maximilian_J_i2019.pdf
1
501E9A968487DEB2D03082EAB847B278
bca5140497959095c0fa9c3ee0e3ecd2ad1510f5c5f645a30af4db24cd69bfa6
8dcd5ca5-17b6-11ed-b6b8-001a4af901a5
https://dirros.openscience.si/Dokument.php?lang=slv&id=17311
https://www.futuremedicine.com/doi/full/10.2217/fon-2019-0346
1
https://dirros.openscience.si/Dokument.php?lang=slv&id=14975
Univerzitetna klinika za pljučne bolezni in alergijo Golnik
0
0
0